CagriSema vs Wegovy: Comparison Guide

CagriSema vs Wegovy: Comparison Guide

The landscape of weight management is evolving rapidly, with new medications offering hope and options for individuals seeking to improve their health. Wegovy (semaglutide) has become a well-known treatment, while a newer investigational medication called CagriSema is generating significant interest.

This guide provides a clear, evidence-aware comparison of these two treatments. It’s designed to help you understand how they work, what the research shows, and what makes them different. Consult your healthcare provider before starting any medication.

Understanding Wegovy (Semaglutide)

Wegovy is an FDA-approved prescription medication for chronic weight management. It's administered as a once-weekly injection and is intended for use alongside a reduced-calorie diet and increased physical activity.

How Wegovy Works

Wegovy’s active ingredient is semaglutide, which belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists.

In simple terms, semaglutide mimics the effects of the natural GLP-1 hormone your body produces after you eat. This hormone plays a crucial role in regulating appetite and food intake. By activating GLP-1 receptors in the brain, Wegovy helps reduce hunger, decrease food cravings, and increase feelings of fullness, leading you to eat less.

What the Research Says

The approval of Wegovy was based on a series of large clinical trials, known as the STEP (Semaglutide Treatment Effect in People with Obesity) program.

Across these studies, participants who took Wegovy, in combination with lifestyle changes, saw significant weight loss. One major trial published in The New England Journal of Medicine found that participants using semaglutide lost an average of nearly 15% of their initial body weight over 68 weeks, compared to just 2.4% for those receiving a placebo.

Introducing CagriSema (Semaglutide and Cagrilintide)

CagriSema is an investigational medication, meaning it has not yet been approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Novo Nordisk submitted it to the FDA in December 2025, and as of October 2026 the review was still under way. It is also a once-weekly injectable treatment.

A Dual-Action Approach

What makes CagriSema different is that it’s a combination drug. It contains two active ingredients:

1. Semaglutide: The same GLP-1 receptor agonist found in Wegovy and Ozempic.
2. Cagrilintide: A long-acting amylin analogue.

Amylin is another natural hormone involved in managing blood sugar and body weight. It is released alongside insulin after a meal and helps promote satiety (the feeling of fullness), slow the rate at which your stomach empties, and suppress the release of glucagon, a hormone that raises blood sugar.

By combining a GLP-1 agonist with an amylin analogue, CagriSema is designed to target two distinct but complementary pathways that regulate appetite and energy balance.

What the Research Says

A Phase 2 trial published in The Lancet in 92 adults with type 2 diabetes compared the combination therapy to semaglutide alone and cagrilintide alone. Over 32 weeks, people on CagriSema lost an average of 15.6% of their body weight, compared with 5.1% on semaglutide alone and 8.1% on cagrilintide alone.

Larger Phase 3 trials have since reported. In REDEFINE 1, in 3,417 adults with obesity or overweight without diabetes, people who stayed on CagriSema lost an average of 22.7% of body weight over 68 weeks, compared with 16.1% on semaglutide 2.4 mg alone (20.4% vs 14.9% when everyone was counted, including those who stopped treatment). In REDEFINE 2, in adults with type 2 diabetes, average weight loss was 15.7% with CagriSema versus 3.1% with placebo.

Key Differences at a Glance

While both treatments aim to support weight loss, their fundamental designs and current status set them apart.

Mechanism of Action

• Wegovy: A single-action medication that works by mimicking one hormone: GLP-1. Its primary effect is on appetite regulation through the GLP-1 pathway.
• CagriSema: A dual-action medication that works by mimicking two hormones: GLP-1 and amylin. It targets two separate biological pathways to influence satiety and appetite.

Efficacy in Clinical Trials

• Wegovy: Proven to be highly effective, with landmark trials showing an average weight loss of around 15% of body weight over 68 weeks.
• CagriSema: In the REDEFINE 1 Phase 3 trial, average weight loss was 20-23% over 68 weeks, more than with semaglutide 2.4 mg alone in the same trial. In a separate head-to-head trial (REDEFINE 4), it produced less weight loss than tirzepatide 15 mg.

Side Effects

Because both medications contain semaglutide, they share a similar profile of potential side effects. The most common are gastrointestinal issues, including nausea, diarrhea, vomiting, constipation, and abdominal pain. These side effects are often mild to moderate and tend to decrease over time as the body adjusts. In REDEFINE 1, gastrointestinal side effects were reported by about 80% of people on CagriSema versus about 40% on placebo. Wegovy's serious risks, such as pancreatitis (severe stomach pain that does not go away and may spread to the back), gallbladder problems and dehydration, would be expected to apply to CagriSema too; seek urgent medical help for these symptoms.

Current Status

• Wegovy: Fully approved and available by prescription in many countries for chronic weight management in eligible individuals.
• CagriSema: An investigational drug under FDA review as of October 2026. It is not available to the public and can only be accessed through participation in a clinical trial. Products sold online as CagriSema are not legitimate.

Which One Might Be Right for You?

The most significant factor right now is availability. Wegovy is an established option that a doctor can prescribe today, whereas CagriSema is not yet on the market.

Making any decision about medication is a personal journey that must be guided by a qualified medical professional. A doctor will consider your complete health profile, including your weight loss goals, co-existing medical conditions, and any other medications you take, to determine the most appropriate and safe course of action.

They can help you understand the risks and benefits of available treatments and decide if a medication like Wegovy is a suitable part of your overall health plan. Consult your healthcare provider before starting any medication.

The Takeaway

Wegovy has established itself as an effective single-hormone-action treatment for chronic weight management, supported by extensive clinical data. CagriSema represents the next wave of innovation, using a dual-hormone approach that has shown promising results in clinical trials.

While the science continues to advance, the core principles of sustainable weight management remain the same: a balanced diet, regular physical activity, and consistent support from healthcare professionals. These medications are tools designed to work with, not in place of, healthy lifestyle habits.

Sources

• STEP 1 trial (NEJM 2021) — PubMed: https://pubmed.ncbi.nlm.nih.gov/33567185/
• CagriSema Phase 2 trial in type 2 diabetes (Frias et al., Lancet 2023): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01163-7/fulltext
• Wegovy prescribing information (FDA): https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
• Novo Nordisk REDEFINE 1 headline results (December 2024): https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915082
• Novo Nordisk REDEFINE 2 headline results (March 2025): https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915294
• Novo Nordisk REDEFINE 4 headline results (February 2026): https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916501
• Novo Nordisk CagriSema NDA submission (December 2025): https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916470
• ACC summary of REDEFINE 1 and REDEFINE 2: https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2025/07/02/14/43/REDEFINE-1-and-REDEFINE-2